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To the Editor:
We have diagnosed a patient from Quebec with
hyperimmunoglobulin M (hyper-IgM) syndrome
resulting from a defect in activation-induced cyti-
dine deaminase (AID). The patient’s mutation
proved to be identical to that of all other French
Canadians with AID defects. This case illustrates
the clinical nature of AID deficiency, and review
of the relevant literature sheds light on what is
being called the “French-Canadian AID 
mutation.”
The patient was referred to our clinic at the age
of 16 years. He had had chronic cervical lym-
phadenopathy since the age of 2 years and also had
recurrent sinopulmonary infections consistent
with bacterial pathogens. He had not experienced
any severe viral or opportunistic infection. One
paternal grandmother and one maternal grand-
mother were sisters. Examination revealed normal
height and weight, cervical lymphadenopathy, a
left middle-ear effusion, and bilateral lower-lobe
expiratory crackles. A chest radiograph was sug-
gestive of bronchiectasis. A complete blood count,
complement levels, and T- and B-cell enumerations
were normal. Levels of all antibodies were low
except that of IgM, which was significantly ele-
vated at 7.93 g/L (normal = 0.56–3.52). The result
of a CD154 binding assay was normal. Sequenc-
ing of the AID gene demonstrated a homozygous
C-to-T mutation at position 334, resulting in cys-
teine replacing arginine at position 112 of the pro-
tein. In every French-Canadian patient with AID
deficiency (there have been 15 such patients if our
patient is included) a homozygous R112C muta-
tion has been found.1 These findings are sugges-
tive of a founder effect.
A founder effect can occur when a small group
of people from one population separate and form
a new population. An allele that had a rare frequency
in the parent population may then have a higher fre-
quency in the new population simply because one
or more of the founders happened to carry the rare
allele. If the new population remains isolated as it
expands, as has been the case in parts of Quebec,
and especially if there is inbreeding,as was the case
in this patient’s family, the founder allele is able
to become homozygous, thus causing autosomal
recessive diseases such as AID deficiency. The
R112C mutation has never been reported in France,
the country of the Quebec founders. This is not sur-
prising because the mutation may have a low fre-
quency in France, and in the absence of inbreed-
ing,it may never manifest as disease. However,one
cannot exclude the possibility that the R112C
mutation did not exist in the Quebec founders but
in fact occurred afterwards. Regardless, genotyp-
ing of polymorphisms surrounding R112C has
demonstrated a single haplotype,and has thus con-
firmed that the mutation originated from a single
individual. In 55 non-French Canadians with AID
deficiency, this mutation was found only once1–3:
a Japanese patient was heterozygous for R112C,
the other AID gene having a premature stop codon.
It is interesting to contemplate whether this patient
had a French or French-Canadian ancestor or
whether the Japanese mutation arose indepen-
dently.
In summary, this case illustrates the typical
clinical manifestations of hyper-IgM syndrome
due to AID deficiency, which differ significantly
from those of hyper-IgM syndrome due to CD154
deficiency: normal growth, the presence of lym-
phadenopathy, infections only of bacterial origin,
and the lack of cytopenias. Our patient’s AID
mutation proved to be identical to that found in all
other French Canadians with this disease, illus-
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